HIF1A and neoplasm: However, it does question the characterization and labeling of HIF1α as a ‘tumor-suppressor’ in kidney cancer based on experimental observations in models with no angiogenesis (in-vitro cell lines) or with deficient immune system (nude mice xenograft).